Icomidocholic acid - Galmed Pharmaceuticals
Alternative Names: Arachidyl amido cholanoic acid; Arachidyl amido cholanoic acid - Galmed Pharmaceuticals; Aramchol; Aramchol - Galmed Pharmaceuticals; Aramchol meglumine - Galmed PharmaceuticalsLatest Information Update: 04 Oct 2024
At a glance
- Originator Galmed Medical Research
- Developer Galmed Medical Research; Galmed Pharmaceuticals; University of California, San Diego
- Class Anti-inflammatories; Antifibrotics; Bile acids and salts; Cholic acids; Drug conjugates; Eicosanoic acids; Eicosanoids; Fatty acids; Gallstone therapies; Hepatoprotectants; Small molecules
- Mechanism of Action Stearoyl-CoA desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Lipodystrophy; Non-alcoholic steatohepatitis
Highest Development Phases
- Phase III Fibrosis; Non-alcoholic steatohepatitis
- Phase II Cholelithiasis; Lipodystrophy; Non-alcoholic fatty liver disease
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 19 Sep 2024 Galmed Pharmaceuticals terminated a phase II trial prior to enrollment in Primary sclerosing cholangitis in the US (NCT06095986)
- 19 Sep 2024 Galmed Pharmaceuticals plans to expand to two additional programs for Liver cancer, Colorectal cancer, Glioma and Cardiovascular disorders
- 17 Jul 2024 Galmed Pharmaceuticals plans a phase I pharmacokinetics trial in Healthy volunteers in Bulgaria (PO) (NCT06502561)